Ozen, AlaattinKocak, ZaferSipahi, TammamOz-Puyan, FulyaCakina, SuatSaynak, MertIbis, Cem2024-06-122024-06-1220131357-05601559-131Xhttps://doi.org/10.1007/s12032-012-0357-yhttps://hdl.handle.net/20.500.14551/22980Analyses of gene expression status and genetic polymorphisms are methods to identify novel histopathological prognostic factors. In patients with gastric cancer, some cell cycle regulators p53, p21, p27 and Her-2 oncogene have been proposed as prognostic factors. We aimed to investigate the expression and mutation/polymorphism of p21 and Her-2 and also relationship between that genes status and histopathological factors and prognosis in patients with gastric cancer. Forty-four patients with locally advanced gastric cancer were analyzed in this study from January 2000 to December 2008. Clinicopathological parameters, expression and mutation/polymorphism of p21 and Her-2 results were used to predict disease-free survival and overall survival. The positive expression of p21 and Her-2 was observed in 61.4 % (n = 27) and 9.1 % (n = 4) of all 44 tumors, respectively. p21 gene mutation and Her-2 gene polymorphism were detected in 20 % (n = 11) and 2.3 % (n = 1, II phenotype) of cases, respectively. The negative expression of p21 was correlated significantly with diffuse and undifferential type histologies, whole gastric involvement and positive vascular/neural invasion. The median survival rate of patients with negative expression was significantly poorer than that of patients with positive expression of p21 (17 vs. 27 months, p = 0.01, cox regression). p21 mutation was significantly higher in patients with diffuse (p = 0.03) and undifferential (p = 0.02) type histologies. There was no statistically significant association between histopathological parameters and Her-2 gene polymorphism/expression. The negative expression of p21 correlates with disease survival and may be a poor prognostic factor in patients with resected gastric cancer treated with adjuvant chemotherapy.en10.1007/s12032-012-0357-yinfo:eu-repo/semantics/closedAccessP21 ExpressionP21 Gene MutationHer-2 ExpressionHer-2 Gene PolymorphismGastric AdenocarcinomaC-Erbb-2 Protein ExpressionShort-Term PrognosisCyclin-ECancerCarcinomaP53P21(Waf1/Cip1)InhibitorWaf1/Cip1StomachArticle301Q3WOS:0003168008000372-s2.0-8488058564223275116Q2